Background-Preclinical systolic or diastolic dysfunction is associated with increased morbidity and mortality. We postulated that plasma brain natriuretic peptide (BNP) might serve as a biomarker for preclinical ventricular dysfunction (PCVD) but that the discriminatory values for BNP may vary with age and sex. Methods and Results-We measured BNP, systolic and diastolic ventricular function, and clinical parameters in 2042 randomly selected residents of Olmsted County, Minn, aged 45 years or older. For preclinical systolic dysfunction, the areas under the receiver operating characteristics curve were higher for those with more severe (0.82 to 0.92) than any (0.51 to 0.74) systolic dysfunction and were similar in men and women and in younger and older persons. For preclinical diastolic dysfunction, the areas under the receiver operating characteristics curve were higher for those with moderate-to-severe (0.74 to 0.79) than any (0.52 to 0.68) diastolic dysfunction and were similar regardless of age or sex.
P reclinical systolic dysfunction is common in the population 1 and is associated with progression to heart failure (HF) and increased mortality. 1, 2 Half of patients with HF have normal ejection fraction (EF), 3 with diastolic dysfunction as the presumed cause of HF symptoms in these patients. In the community, diastolic dysfunction is common and is predictive of HF and death. 4 -6 Although more data are needed before screening for and treatment of preclinical ventricular dysfunction (PCVD) can be recommended in the community, 1 an adequate screening test is needed before efficacy of screening strategies can be evaluated.
As recently summarized, several studies have evaluated the predictive characteristics of BNP for detecting preclinical systolic dysfunction in different settings and with different conclusions. 1 Although a study in a clinical population suggested that BNP may have value for detection of diastolic dysfunction, 7 no study has evaluated BNP for the detection of preclinical diastolic dysfunction in the general population.
In the present study, we assessed the ability of BNP to detect preclinical systolic or diastolic dysfunction in the population and in a high-risk subset (age Ն65 years and with known cardiovascular disease). Because BNP is higher in female subjects and increases with age among subjects without cardiovascular disease, 8, 9 we also sought to determine if age and sex influence the predictive characteristics or discriminatory value of BNP. Finally, the implications of the predictive characteristics of BNP for screening were explored, accounting for the prevalence of PCVD in the population.
Methods
The Mayo Foundation Institutional Review Board approved this study.
Study Setting
Using the resources of the Rochester Epidemiology Project, 10 a random sample of Olmsted County, Minn, residents age Ն45 years was identified. The characteristics of the Olmsted County, Minn, population, the unique aspects of epidemiological research in this population, and the methodologies used in identifying this cohort have been described previously. 6 
Medical Record Review
Community medical records were reviewed by trained nurse abstractors to determine if participants had a history of hypertension, myocardial infarction, coronary artery disease, diabetes mellitus, or HF (Framingham criteria), as previously described. 6 Subjects without a validated HF diagnosis but with ventricular dysfunction were considered to have PCVD, as previously described. 6 A high-risk subset of the population was defined as subjects age Ն65 years who had a recognized diagnosis of cardiovascular disease (hypertension or coronary artery disease).
Doppler Echocardiography
The echocardiographic methods used in this study have been previously described in detail. 6 EF was measured by M-mode, quantitative 2D, and semiquantitative 2D (visual estimate) methods in each subject. Correlation among methods was excellent. The semiquantitative method was available in more than 99% of subjects and was used in this analysis. Pulsed-wave Doppler examination of mitral (before and with Valsalva maneuver) and pulmonary venous inflow and Doppler tissue imaging of the mitral annulus were performed in each subject. Diastolic function was categorized as normal, impaired relaxation (mild diastolic dysfunction), impaired relaxation associated with moderate elevation of filling pressures (pseudonormal filling-moderate diastolic dysfunction), and advanced reduction in compliance (restrictive filling-severe diastolic dysfunction), as previously described 6 and validated. 11, 12 
BNP Analysis
Blood for BNP was collected on the same day as the echocardiogram in the fasting state. Samples were processed and analyzed using the Biosite fluorescence immunoassay system as previously described. 8 
Statistical Methods
The distribution of BNP was summarized as a median with corresponding 5th, 25th, 50th, 75th, and 95th percentiles. Because BNP was not normally distributed, the bivariate association of natural log BNP with age, sex, EF, and diastolic dysfunction was investigated using the Pearson's correlation coefficient (r) for continuous variables and the Wilcoxon rank-sum test for categorical variables. Multivariable associations of log BNP with age, sex, and EF as well as age, sex, and diastolic dysfunction were assessed using leastsquares regression. Potential interactions of age and sex with EF and diastolic dysfunction were also evaluated when considering the association of these variables with BNP. Receiver operating characteristics (ROC) analyses were used to assess the predictive accuracy of BNP for detecting EF Յ50%, EF Յ40%, any diastolic dysfunction, and moderate-to-severe diastolic dysfunction and were compared using the method of DeLong et al. 13 The optimal cutoff for each end point was the corresponding BNP that resulted in a sensitivity and specificity closest in distance to the point of a perfect marker (ie, sensitivity of 100% and specificity of 100%).
Results
The baseline characteristics of the study sample and the high-risk subgroup are shown in Table 1 . Subjects with HF were excluded from the remainder of the analysis.
Impact of Age and Sex on the Relationship Between BNP and PCVD
The distribution of BNP according to the level of EF and age or sex is shown in Figure 1 . The distribution of BNP was shifted upward as EF decreased in older (Ն65 years of age) persons (rϭϪ0.144, PϽ0.0001) and in men (rϭϪ0.202, PϽ0.0001), but this relationship was not observed in younger persons (rϭ0.058, Pϭ0.052) or in women (rϭ0.004, Six subjects (4 in the high-risk subgroup) had no EF measurement, and 173 subjects had indeterminate diastolic function analysis (85 in the high-risk subgroup).
*Percentages indicate prevalence of systolic or diastolic dysfunction among all subjects in the total population (nϭ2042) or high-risk group (nϭ431).
Pϭ0.910).
In subjects with normal systolic function, BNP was higher in older persons (PϽ0.0001) and higher in women (PϽ0.0001). In subjects with an EF Յ50%, BNP tended to be higher in older persons (Pϭ0.328) and was higher in women (PϽ0.0001). The difference in BNP with age (Pϭ0.576) and sex (Pϭ0.543) was not apparent in subjects (nϭ20) with an EF Ͻ40%. In multivariable models, the positive association of age (Pϭ0.0007) or female sex (PϽ0.0001) with BNP was still apparent when controlling for EF.
The distribution of BNP according to the level of diastolic dysfunction and age or sex is shown in Figure 2 . The distribution of BNP shifted upwards as the severity of diastolic dysfunction increased in all subjects (rϭ0.308, PϽ0.0001), older persons (rϭ0.286, PϽ0.0001), younger persons (rϭ0.098, Pϭ0.0017), men (rϭ0.356, PϽ0.0001), and women (rϭ0.294, PϽ0.0001). In subjects with normal diastolic function, BNP was higher in older persons (Pϭ0.0001) and was higher in women (Pϭ0.0001). In subjects with any diastolic dysfunction, BNP was higher in older persons (Pϭ0.0001) and in women (Pϭ0.0001). In subjects with moderate or severe diastolic dysfunction, BNP was higher in older persons (Pϭ0.0001) and tended to be higher in women (Pϭ0.139). In multivariable models, the positive association of age (Pϭ0.0003) and female sex (Pϭ0.013) with BNP was still apparent when controlling for severity of diastolic dysfunction.
Receiver Operating Characteristics Analysis
The results of ROC analysis for the detection of preclinical systolic ( Figure 3 ) and diastolic ( Figure 4 ) dysfunction according to age and sex in the population are shown. The area under the ROC curves (AUC) and the upper and lower confidence intervals for the estimated AUC for the detection of EF Յ50% and EF Յ40% are displayed. Among all subgroups, the AUC was higher for the detection of EF Յ40% than for detection of EF Յ50%. The AUC for detection of EF Ͻ50% was similar in older and younger persons (Pϭ0.99) and in men and women (Pϭ0.475). The AUC for detection of EF Ͻ40% was again similar regardless of age group (Pϭ0.428) and sex (Pϭ0.334). Among all subgroups, the AUC was higher for the detection of moderate or severe diastolic dysfunction than for detection of any diastolic dysfunction. The AUC for detection of any diastolic dysfunction was similar between older and younger persons (Pϭ0.922) and between men and women (Pϭ0.774). The AUC for detection of moderate or severe diastolic dysfunction was similar regardless of age group (Pϭ0.550) and sex (Pϭ0.560). In the total population without HF, 7.5% had "any" significant ventricular dysfunction, defined as EF Յ40% or moderate-to-severe diastolic dysfunction. The AUC for detection of any significant preclinical dysfunction was 0.79 (0.75 to 0.84), with an optimal BNP partition value of 25.9 pg/mL, having a sensitivity of 62% and a specificity of 63%. Using the age-and sex-adjusted normal BNP values for the partition values yielded a sensitivity of 44% and a specificity of 91%. The AUC was similar in men (0.82) and women (0.79) and in the high-risk group (0.74).
In the high-risk subgroup (nϭ396), the AUC for the detection of EF Յ40% was 0.82 (confidence interval, 0.71 to 0.93) in men and 0.74 (no confidence interval available because of low prevalence of EF Յ40%) in women. The AUC for the detection of moderate or severe diastolic dysfunction was 0.74 (0.62 to 0.86) in men and 0.73 (0.61 to 0.84) in women.
Implications for Screening
The AUCs for detection of EF Ͻ50% or mild diastolic dysfunction were consistently Ͻ0.70 and likely insufficient to allow their use as a screening test. Thus, we confined our further analysis to use of BNP to detect EF Յ40% or moderate or severe diastolic dysfunction.
The optimal BNP (from ROC analysis) for the detection of EF Յ40% or moderate or severe diastolic dysfunction according to age and sex in the population and in the high-risk group are shown in Tables 2 and 3 . The optimal discriminatory BNP was higher in subjects older than age 65 years than in the total population and higher in women than in men both in the total population and in the high-risk group.
The sensitivity and specificity of BNP using the optimal discriminatory BNP or using a discriminatory value based on age-and sex-specific upper normal ranges 8 are shown in Table 2 (for detection of EF Ͻ40%) and Table 3 (for detection of moderate or severe diastolic dysfunction). The prevalence of PCVD, the positive and negative likelihood ratios, the percentage of subjects screened who would need echocardiography (because of an abnormal BNP), the percent of echocardiograms that would be negative (false-positives), and the percent of those with the abnormality who would be missed (false-negatives) are displayed. The low prevalence of preclinical systolic dysfunction and the observed specificity mean that a large segment of the population screened would need an echocardiogram and that nearly all of these would be negative. Using a more specific discriminatory value based on upper normal value results in the need for fewer confirmatory echo studies but fails to detect at least 30% of those with preclinical systolic dysfunction. For detection of moderate or severe diastolic dysfunction, sensitivity, specificity, and the likelihood ratios are less robust. Using the optimal discriminatory value again results in a large percentage of the screened population requiring an echo, with most being negative and 20% to 40% of those with diastolic dysfunction being missed. Using the more specific upper normal value reduces the number of echocardiograms needed but misses more (40% to 60%) of those with diastolic dysfunction.
Discussion
Early detection and treatment of PCVD is suggested as an effective strategy to prevent or delay the onset of HF. Such a strategy would mandate screening for PCVD in the general population or high-risk subgroups. The United States Preventive Services Task Force and similar scientific groups advocate the following 3 minimum criteria for assessing screening: 14, 15 (1) demonstration of the burden of suffering, ie, the prevalence and morbidity/mortality of the disease screened for; (2) an accurate screening test; and (3) evidence that early detection is effective, ie, screening (and subsequent intervention) reduces morbidity and mortality. Although the burden of suffering associated with PCVD has been established, the efficacy and cost of therapy, particularly in the context of a community screening and intervention strategy, remain poorly quantified, and to date, no ideal screening test exists. 1 Few screening strategies have conclusively filled these 3 criteria and been uniformly endorsed by the United States Preventive Services Task Force and similar scientific groups. Indeed, much of the controversy about screening focuses on the performance characteristics of initial screening tests, which will require validation by more expensive definitive diagnostic tests. The relatively low prevalence of diseases screened for and the high costs of diagnostic testing fuel concerns in this era of limited societal resources for medical care.
A few studies have evaluated the performance of BNP for detection of preclinical systolic dysfunction in populationbased studies but with different approaches and different conclusions. Our findings on the use of BNP to screen for preclinical systolic dysfunction are similar to those previously reported by Vasan et al 16 in the Framingham Heart Study (FHS) cohort. In that study, the AUCs for BNP to detect moderate-to-severe preclinical systolic dysfunction were 0.79 and 0.85, compared with 0.89 and 0.92 in the present study in men and women, respectively. These values are also similar to those observed in a small general practicebased study in the United Kingdom 17 and in a smaller population-based study in Germany. 18 In the FHS study and here, the prevalence of moderate-to-severe systolic dysfunction is relatively low (although substantial from a public health standpoint) and raises concerns about the ultimate cost-effectiveness of the test, because relatively large numbers of screened subjects would require echocardiograms. Nielsen et al 19 reported that BNP with follow-up echocardiography was more cost-effective than echocardiography for ruling out systolic dysfunction in a cohort of subjects from the MONICA study. However, many would argue that a "rule-in" strategy is more appropriate when screening for abnormalities in populations with low prevalence. 1, 16, 20 A preliminary analysis of the cost-effectiveness of screening suggested that screening for preclinical systolic dysfunction could be cost-effective in elderly men. 21 However, this analysis did not factor in the impact of repeated screening and relied on clinical trials to estimate benefit of treatment, assumptions that may not be valid in community-based populations. Both the FHS study and the present study suggest that BNP is considerably less accurate for detection of milder degrees of systolic dysfunction, which is more common and also associated with increased risk. 2 A screening tool that does not reliably detect milder levels of systolic dysfunction would limit ability to impact events. Lastly, high ϩLR indicates positive likelihood ratio; ϪLR, negative likelihood ratio. *Age-and sex-adjusted reference ranges, as previously described.
